Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
AO GENERIUM clinical trials
The registry lists 31 studies whose lead sponsor is AO GENERIUM. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 30, 2026.
Keep track of what changes. Save the AO GENERIUM studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to AO GENERIUM.
- AO GENERIUM31 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 31 of 31.
- A Study to Compare GNR-139 and Eylea® in Patients With nAMDRecruitingNCT07844148Phase 3
- A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therapy in Pediatric Patients With Duchenne Muscular DystrophyRecruitingNCT07673809Phase 1/2
- Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®RecruitingNCT04667039Phase 3
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type IIActive, not recruitingNCT05208281Phase 2/3
- Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial InfarctionCompletedNCT05601999Phase 3
- GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALLTerminatedNCT04601584Phase 1/2
- An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque PsoriasisCompletedNCT06488664Phase 3
- A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy VolunteersCompletedNCT06488521Phase 1
- A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis.CompletedNCT07155499Phase 1/2
- A Phase 1 Study of GNR-051 in Subjects With Advanced MalignanciesCompletedNCT04544748Phase 1
- Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial InfarctionCompletedNCT07146360Phase 3
- An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's DiseaseCompletedNCT06497491Phase 3
- A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy VolunteersCompletedNCT06494345Phase 1
- A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy VolunteersCompletedNCT06475404Phase 1
- Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid ArthritisCompletedNCT06475508Phase 3
- A Safety, Pharmacokinetics and Pharmacodynamics Study of GNR-086 and Ilaris® in Healthy VolunteersCompletedNCT06481189Phase 1
- A Safety and Pharmacokinetic Study of Complarate (Tocilizumab Biosimilar) and Actemra® in Healthy VolunteersCompletedNCT06481202Phase 1
- A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy VolunteersCompletedNCT06481215Phase 1
- Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP PatientsCompletedNCT05492409Phase 3
- Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITPCompletedNCT05220878Phase 3
- Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®CompletedNCT04671810
- Observational Study of Elizaria® in aHUS PatientsCompletedNCT04749810
- Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary AngioedemaWithdrawnNCT04898309Phase 2/3
- Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNHCompletedNCT04463056Phase 3
- A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)CompletedNCT04679103Phase 3
- An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial AsthmaCompletedNCT04607629Phase 3
- Study of Pharmacokinetics, Pharmacodynamics and Safety Assessment of GNR-044 (JSC GENERIUM, Russia) and Xolair®CompletedNCT04601389Phase 1
- A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy VolunteersCompletedNCT04539340Phase 1
- Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19CompletedNCT04459325Phase 3
- Safety and Pharmacokinetics of GNR-038 in Healthy VolunteersCompletedNCT04557319Phase 1
- Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic FibrosisCompletedNCT04468100Phase 3